
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. is poised for growth as its flagship molecule, cabozantinib, maintains its position as a leading treatment for renal cell carcinoma (RCC), bolstered by robust long-term data and recent label expansions into neuroendocrine tumors (NETs). The encouraging performance of zanzalintinib in combination with atezolizumab demonstrates statistically significant improvements in overall survival, enhancing the outlook for this asset as it gains traction in the market. As Exelixis continues to build on its successes and explore new indications, the overall positive trajectory of its products fosters a favorable investment sentiment in the biopharmaceutical sector.
Bears say
Exelixis Inc. is facing significant financial challenges, particularly with the anticipated 80% revenue decline by 2032 due to the impending patent expiration in 2031, which contrasts sharply with the market's more optimistic expectation of a 68% decline. The company also encounters competitive risks that could further jeopardize its market position, including potential erosion of market share for its primary drug, cabozantinib, across various oncology indications and disappointing data from its pipeline programs. Additionally, there are considerable developmental risks associated with its other treatments, notably zanzalintinib, which contribute to a cautious outlook on the company's financial prospects.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares